ANTIPHOSPHOLIPID SYNDROME (APS)
Clinical trials for ANTIPHOSPHOLIPID SYNDROME (APS) explained in plain language.
Never miss a new study
Get alerted when new ANTIPHOSPHOLIPID SYNDROME (APS) trials appear
Sign up with your email to follow new studies for ANTIPHOSPHOLIPID SYNDROME (APS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets immune diseases in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called RAY121 in people with six different immune system diseases, including antiphospholipid syndrome and bullous pemphigoid. The main goal is to check safety and how the body processes the drug. About 144 adults will take part to see if t…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated May 17, 2026 09:02 UTC
-
Experimental cell therapy targets tough autoimmune conditions
Disease control Recruiting nowThis early-phase study tests a new cell treatment called YTS109 in 18 adults with severe autoimmune diseases like lupus and vasculitis that have not responded to standard therapies. Participants receive a single infusion of these specially engineered cells. The main goal is to ch…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 08:54 UTC
-
New cell shot aims to tame Out-of-Control immune attacks
Disease control Recruiting nowThis early study tests a new cell treatment called YTS109 in 18 adults with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. Participants get a single infusion of these specially designed cells. The main goal is to see if the treatme…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New study aims to find best blood thinner for rare clotting disorder
Knowledge-focused Recruiting nowThis study looks at 600 adults with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots. Researchers are comparing two types of blood thinners—direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)—to see which works better at preventing …
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Sponsor: Infanta Leonor University Hospital • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC
-
New study tracks blood clot risks in rare autoimmune disease
Knowledge-focused Recruiting nowThis study follows 200 adults with antiphospholipid syndrome (APS), a rare condition that increases blood clot risk. Researchers will track how often clots return and look at side effects from current treatments. The goal is to update old data and better understand real-world out…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Apr 24, 2026 16:06 UTC